Ebitda Perubahan Tanggal
ALKERMES USD 80.26M 20.05M 2026-03
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amarin USD 12.54M 28.57M 2025-06
ANI Pharmaceuticals USD 65.36M 5.76M 2025-12
Anika Therapeutics USD 4.54M 3.67M 2025-12
Arrowhead Research USD 57.17M 7.03M 2025-12
Eisai JPY -335M 30.43B 2026-03
Esperion Therapeutics USD -9.93M 24.99M 2025-09
GlaxoSmithKline GBP 2.77B 1.65B 2026-03
Heron Therapeutics USD -3.88M 5.63M 2024-09
Insmed USD -148.3M 165.88M 2026-03
Ligand Pharmaceuticals USD 66.78M 83.54M 2025-12
Merck USD 6.3B 2.09B 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Omeros USD -47.96M 7.39M 2023-09
Pacira USD 40.24M 1.53M 2026-03
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Veracyte USD 42.8M 488K 2026-03
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03